Major Molecular Response in CML Patients Treated with Tyrosine Kinase Inhibitors: The Paradigm for Monitoring Targeted Cancer Therapy

被引：8
|
作者：
Press, Richard D. [1 ,2 ]
机构：
[1] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA
[2] Oregon Hlth & Sci Univ, Dept Pathol, Portland, OR 97201 USA
来源：
ONCOLOGIST | 2010年 / 15卷 / 07期
关键词：
Chronic myeloid leukemia; Tyrosine kinase inhibitor; BCR-ABL; Imatinib; CHRONIC MYELOID-LEUKEMIA; HARMONIZING CURRENT METHODOLOGY; MESSENGER-RNA LEVELS; BCR-ABL TRANSCRIPTS; DOMAIN MUTATIONS; IMATINIB; PREDICTS; RECOMMENDATIONS; NILOTINIB; INTERFERON;
D O I：
10.1634/theoncologist.2010-0055
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：744 / 749
页数：6
相关论文
共 50 条
  • [1] THE STUDY OF THE INFLUENCE OF PRIOR THERAPY ON RESPONSE TO TYROSINE KINASE INHIBITORS THERAPY IN CML PATIENTS
    Perekhrestenko, T.
    Dyagil, I.
    Dmytrenko, I.
    Tretyak, N.
    Gordienko, A.
    HAEMATOLOGICA, 2013, 98 : 566 - 566
  • [2] CML PATIENTS TREATED BY TYROSINE KINASE INHIBITORS IN FIRST CHRONIC PHASE: IMPACT OF MAJOR MOLECULAR RESPONSE ON OVERALL SURVIVAL AND DELAY OF ITS ACHIEVEMENT ON COMPLETE MOLECULAR RESPONSE INCIDENCE
    Michallet, M.
    Sobh, M.
    Morisset, S.
    Ducastelle, S.
    Gilis, L.
    Etienne, M.
    Le Borgne, O.
    Tigaud, I.
    Hayette, S.
    Thomas, X.
    Labussiere, H.
    Barraco, F.
    HAEMATOLOGICA, 2014, 99 : 600 - 601
  • [3] Cardiotoxicity Monitoring in Patients Treated with Tyrosine Kinase Inhibitors
    Skubitz, Keith M.
    ONCOLOGIST, 2019, 24 (07): : E600 - E602
  • [4] EXPERIENCE IN A CENTER OF SUSPENSION OF TYROSINE KINASE INHIBITORS IN PATIENTS WITH CML IN PROLONGED COMPLETE MOLECULAR RESPONSE
    De Poo Rodriguez, V
    Auria Caballero, C.
    Moreno Chulilla, J.
    Alvarez Mancenido, F.
    Campos Montellano, F.
    Pimentel Feliciano, A.
    Amarilla Lanzas, I
    Dourdil Sahun, V
    Bonafonte Arruga, E.
    Mayor Perez, L.
    Martinez Lazaro, B.
    Asensio Del Rio, A.
    Martinez Lazaro, B.
    Palomera Bernal, L.
    HAEMATOLOGICA, 2019, 104 : 299 - 299
  • [5] Predicting the Response of CML Patients to Tyrosine Kinase Inhibitor Therapy
    White, Deborah L.
    Hughes, Timothy P.
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2011, 6 (02) : 88 - 95
  • [6] Predicting the Response of CML Patients to Tyrosine Kinase Inhibitor Therapy
    Deborah L. White
    Timothy P. Hughes
    Current Hematologic Malignancy Reports, 2011, 6
  • [7] Adherence, persistence, and molecular response patterns in patients with CML treated with tyrosine kinase inhibitors in an integrated health system specialty pharmacy
    Narayanan, Bisni
    Riccardi, Michele
    Territo, Christopher
    Levay, Thomas
    Cadorette, Andrew
    Rubino, Terri Sue
    Abdelghany, Sam
    Sawant, Vinay
    Do, Tina
    CURRENT MEDICAL RESEARCH AND OPINION, 2024, 40 : S9 - S9
  • [8] Predicting the response of CML patients to tyrosine kinase inhibitor therapy
    White D.L.
    Hughes T.P.
    Current Hematologic Malignancy Reports, 2009, 4 (2) : 59 - 65
  • [9] A review on tyrosine kinase inhibitors for targeted breast cancer therapy
    Sankarapandian, Vidya
    Rajendran, Ramya Lakshmi
    Miruka, Conrad Ondieki
    Sivamani, Poornima
    Maran, Balu Alagar Venmathi
    Krishnamoorthy, Rajapandiyan
    Gangadaran, Prakash
    Ahn, Byeong-Cheol
    PATHOLOGY RESEARCH AND PRACTICE, 2024, 263
  • [10] Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy
    Pottier, Charles
    Fresnais, Margaux
    Gilon, Marie
    Jerusalem, Guy
    Longuespee, Remi
    Sounni, Nor Eddine
    CANCERS, 2020, 12 (03)
12345